Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis
Manuel Rubio‐Rivas, Carlos G. Forero, José María Mora‐Luján, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2021) Vol. 41, Iss. 11, pp. 884-906
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

The roles of critical pro‐inflammatory cytokines in the drive of cytokine storm during SARS‐CoV‐2 infection
Muhammad Suhaib Qudus, Mingfu Tian, Summan Sirajuddin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 46
Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression
Cameron Bishop, Troy Dumenil, Daniel J. Rawle, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 9, pp. e1010867-e1010867
Open Access | Times Cited: 27
¿Qué factor predice mejor el pronóstico en pacientes con COVID-19: los biomarcadores analíticos o la relación PaO2/FiO2?
Manel Rubio-Rivas, José María Mora‐Luján, Abelardo Montero Sáez, et al.
Revista Clínica Española (2025)
Closed Access
Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
Carolina García‐Vidal, Júlia de Oliveira Gonzalez, Carlos Lumbreras, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis
Norah Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis
Soheila Rezaei, Behzad Fatemi, Zahra Karimi Majd, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 5, pp. 499-511
Open Access | Times Cited: 33
Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era
Cori Campbell, Monique Andersson, M. Azim Ansari, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 33
Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium
Jordi Rello, Mirko Belliato, Meletios Α. Dimopoulos, et al.
Anaesthesia Critical Care & Pain Medicine (2020) Vol. 39, Iss. 6, pp. 723-730
Open Access | Times Cited: 38
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Reza Malekzadeh, Atefeh Abedini, Behzad Mohsenpour, et al.
International Immunopharmacology (2020) Vol. 89, pp. 107102-107102
Open Access | Times Cited: 35
Angiopathic activity of LRG1 is induced by the IL-6/STAT3 pathway
Athina Dritsoula, Laura Dowsett, Camilla Pilotti, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication
Boris Hügle, Manuela Krumrey-Langkammerer, Johannes‐Peter Haas
Pediatric Rheumatology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
Jerin Jose Cherian, Madhavi Eerike, Bhavani Shankara Bagepally, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 11
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
Rahnuma Ahmad, Mainul Haque
Vaccines (2022) Vol. 10, Iss. 4, pp. 614-614
Open Access | Times Cited: 10
Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants
Oleksandr Oliynyk, Wojciech Barg, Yanina Oliynyk, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 10
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Alexia Plocque, Christie Mitri, Charlène Lefèvre, et al.
Drugs (2022) Vol. 83, Iss. 1, pp. 1-36
Open Access | Times Cited: 8
Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression
Cameron Bishop, Troy Dumenil, Daniel J. Rawle, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry
Manuel Rubio‐Rivas, José María Mora‐Luján, Francesç Formiga, et al.
Internal and Emergency Medicine (2022) Vol. 17, Iss. 4, pp. 1115-1127
Open Access | Times Cited: 6
High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells
Bo Wang, Dongping Li, Anna Fiselier, et al.
Heliyon (2023) Vol. 9, Iss. 8, pp. e18817-e18817
Open Access | Times Cited: 3
Drug dosing in hospitalized obese patients with COVID-19
Jeffrey F. Barletta, Brian L. Erstad
Critical Care (2022) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Modeling mechanisms underlying differential inflammatory responses to COVID-19 in type 2 diabetes using a patient-derived microphysiological organ-on-a-chip system
Vinny Negi, Dillon Gavlock, Mark T. Miedel, et al.
Lab on a Chip (2023) Vol. 23, Iss. 20, pp. 4514-4527
Closed Access | Times Cited: 2
Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation
Tyler Lewis, Serena Arnouk, Bridget Toy, et al.
ASAIO Journal (2022) Vol. 68, Iss. 8, pp. 1010-1016
Open Access | Times Cited: 4
Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols
Engy Elekhnawy, Walaa A. Negm, Suzy A. El-Sherbeni, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 1935-1954
Open Access | Times Cited: 4
Dexamethasone Vs methylprednisolone In treating Covid-19 pneumonia: A meta-analysis of randomized trials
Fatma Ahmed Abdelfatah, Ahmed Abd El-Hamid, Abeer Soliman Emara, et al.
Benha Medical Journal (2024)
Open Access
Page 1 - Next Page

Scroll to top